Scisparc Announced Receiving 180-day Extension By NASDAQ To Regain Compliance With Minimum Bid Requirement
Portfolio Pulse from Benzinga Newsdesk
SciSparc Ltd. (NASDAQ:SPRC), a clinical-stage pharmaceutical company, has been granted a 180-day extension by Nasdaq to regain compliance with the minimum bid price rule. The company now has until March 4, 2024, to meet this requirement.
September 07, 2023 | 10:09 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
SciSparc has been granted an extension by Nasdaq to regain compliance with the minimum bid price rule. This could potentially alleviate some pressure on the company in the short term.
The extension granted by Nasdaq provides SciSparc with additional time to regain compliance with the minimum bid price rule. This could potentially alleviate some immediate pressure on the company, but it does not guarantee that the company will be able to meet the requirement within the extended period. Therefore, the short-term impact on the stock price is neutral.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100